9:00 am Formulating Innovative & Patient Centred Phase 3 Trials to Improve Results for Translating More Drugs to Clinic
Time: 9:00 am
day: Conference Day 2
Details:
- Designing Phase III MASH trials to integrate robust methodologies and evaluating efficacy and safety across diverse patient populations, accelerating the path to regulatory approval to bring therapies to patients faster
- Incorporating non-invasive testing throughout Phase III trials to reduce patient burden and enhance data collection efficiency, leading to more comprehensive and patient-friendly assessments of treatment response
- Implementing patient retention strategies to ensure sustained participation in long-term Phase III studies, providing more complete and reliable data for demonstrating durable treatment benefits
